US allows increased production of Takeda's ADHD drug and its generics to address shortage
Corrects headline and paragraph 1 to make clear Takeda's drug is not in shortage
Sept 4 (Reuters) -The U.S. Drug Enforcement Administration has increased the production limit for Takeda Pharmaceutical's 4502.T ADHD drug Vyvanse and its generic versions by about 24% to address the ongoing shortage of the copiesin the United States.
The raised production limit follows the Food and Drug Administration's request in July, the DEA said in a notice on Tuesday.
Attention deficit hyperactivity disorder (ADHD) drugs have been in short supply for years. The FDA warned of a shortage of Israel-based drugmaker Teva Pharmaceutical Industries' TEVA.TA Adderall in October 2022, troubled by manufacturing delays.
That led to a spike in demand and subsequent shortage of Takeda's Vyvanse.
Vyvanse, also known as lisdexamfetamine, is classified by the DEA as a schedule II controlled substance, which is applied to drugs considered to have a high likelihood of being abused, and additional prescribing safeguards are put in place.
The production limit for lisdexamfetamine was increased by 6,236 kilograms, which includes 1,558 kg to address increased domestic demand and 4,678 kg for increased foreign demand for finished dosage medications, according to the DEA.
"These adjustments are necessary to ensure that the United States has an adequate and uninterrupted supply of lisdexamfetamine to meet legitimate patient needs both domestically and globally," DEA said.
The FDA approved generic versions of Vyvanse from 11 drugmakers, including U.S.-based drugmakers Mallinckrodt and Viatris VTRS.O, UK-based Hikma Pharmaceuticals HIK.L, and Indian drugmaker Sun Pharmaceutical Industries SUN.NS, last year after Takeda lost exclusivity over the drug.
Bloomberg News first reported about the increased limits on Tuesday.
Reporting by Mariam Sunny in Bengaluru; Editing by Vijay Kishore
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
